Get the Stockscreener App
62.55
0.76%
0.465
After Hours:
62.56
0.005
+0.01%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $62.55, with a volume of 7.39M.
It is up +0.76% in the last 24 hours and up +8.76% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$62.09
Open:
$62.4
24h Volume:
7.39M
Relative Volume:
0.65
Market Cap:
$127.76B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
17.56
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
+3.99%
1M Performance:
+8.76%
6M Performance:
+12.60%
1Y Performance:
+29.18%
1-Day Range:
$62.22
$63.44
1-Week Range:
$59.80
$63.44
52-Week Range:
$42.52
$63.44
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
62.56 | 126.79B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,197.31 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
265.99 | 634.77B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.92 | 458.24B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
130.72 | 323.72B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.10 | 294.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Theo Ai Appoints Former Bristol Myers Squibb General Counsel Sandra Leung to Board - citybiz
Bristol-Myers Squibb stock hits 52-week high at 62.89 USD - Investing.com
BMO reiterates Bristol-Myers Squibb stock rating on Cobenfy edge By Investing.com - Investing.com India
Theo Ai Appoints Former Bristol Myers Squibb General Counsel Sandra Leung to Board of Directors - citybiz
Bristol Myers Squibb stock holds gains as Takeda partnership and Revlimid erosion shape outlook - Ad-hoc-news.de
Theo Ai Bolsters Leadership, Appoints Sandra Leung, Former Bristol Myers Squibb General Counsel, to Board of Directors - PR Newswire
BMS launches dual immunotherapy for metastatic melanoma - The Hindu
Bristol Myers Squibb stock reacts to latest Opdivo data and solid 2024 outlook - Ad-hoc-news.de
BMY|Bristol-Myers Squibb Co|Price:62.090|Chg%:+0.580 - TradingKey
Bristol Myers Squibb stock trades steadily as Eliquis and Opdivo anchor earnings and guidance - Ad-hoc-news.de
Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now - Kavout | AI
Bristol Myers Squibb stock reacts as cancer and cardiovascular pipeline updates follow recent earnin - Ad-hoc-news.de
Bristol-Myers Squibb’s High Dividend Temporarily Backed by Financial Support, but Patent Cliff Poses Future Concerns - NAI500
Is Bristol Myers Squibb's Dividend Too Good to Be True? Here's My Honest Answer - The Motley Fool
Is Bristol Myers Squibb's Dividend Too Good to Be True? Here's My Honest Answer - The Motley Fool
Bristol-Myers Squibb Co (BMY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bristol-Myers Squibb Co (BMY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bristol-Myers Squibb Company (BRM.F) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Bristol-Myers Squibb stock trades steady as Opdivo and Eliquis underpin revenue and margins - Ad-hoc-news.de
Bristol Myers Squibb stock steadies as investors weigh Karuna buyout and latest oncology data - AD HOC NEWS
Oak Associates Ltd. OH Acquires New Position in Bristol Myers Squibb Company $BMY - MarketBeat
Public Employees Retirement System of Ohio Has $51.79 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Why Investors Are Watching Bristol Myers Squibb, Gilead Sciences and Amgen - Kalkine Media
Bristol Myers Squibb Company $BMY Stake Raised by Sei Investments Co. - MarketBeat
Why Is Bristol Myers Squibb (NYSE:BMY) On S&P 500 Radar? - Kalkine Media
Compound Planning Inc. Has $4.94 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Arrowstreet Capital Limited Partnership Has $538.13 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Co (BMY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bristol Myers Squibb stock trades steady as cardiovascular and oncology pipeline shapes outlook - AD HOC NEWS
Bristol-Myers Squibb Company (BMY) Options Chain - Yahoo! Finance Canada
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
DOL Brief Sides With Bristol-Myers in PRT Appeal - planadviser
Bristol Myers Squibb stock steadies as investors weigh Revlimid erosion against new product launches - AD HOC NEWS
BMY|Bristol-Myers Squibb Co|Price:61.520|Chg%:+0.010 - TradingKey
DOL Anchors Wave of Briefs Backing Bristol-Myers in PRT Appeal - plansponsor
DOL Takes Swipe At Derisking Cases In Bristol-Myers Brief - Law360
Bristol Myers Squibb stock stabilizes as Eliquis and Opdivo help offset Revlimid erosion - AD HOC NEWS
Donald TrumpBRISTOL MYERS SQUIBB CO Trump Trade on May. 18, 2026 - Quiver Quantitative
Bristol Myers Squibb stock steadies as Eliquis and Opdivo shape earnings outlook - AD HOC NEWS
Bristol Myers Squibb (BMY) Wins FDA Filing And Nvidia Tie Up, Is It Still Undervalued? - simplywall.st
Alexandria Real Estate Equities (ARE) Delivers 427,000 RSF Bristol Myers Squibb R And D Hub - Yahoo Finance Singapore
Bristol Myers Squibb stock edges higher as recent results and oncology portfolio shape investor view - AD HOC NEWS
Bristol Myers Squibb Partners With NVIDIA to Build Pharma's Largest Supercomputer - Mjengo Hub
Bristol Myers Squibb Supercharges Drug Discovery With NVIDIA AI - Sahm
Bristol Myers Squibb (BMY) Opens 427,000 Square Foot San Diego Hub For AI Drug Discovery - Yahoo Finance UK
Bristol Myers Squibb stock trades steadily as oncology and immunology portfolio supports earnings tr - AD HOC NEWS
Bristol Myers Squibb stock trades steadily as oncology pipeline and recent earnings shape sentiment - AD HOC NEWS
Bristol Myers Squibb stock trades steadily as oncology pipeline and Revlimid erosion shape outlook - AD HOC NEWS
BMS: Boosting AI Drug Discovery Capacity with NVIDIA Tech - Healthcare Digital
Bristol Myers Squibb Expands AI Infrastructure With NVIDIA to Build AI Factory for Drug Discovery - Digital Health News
Bristol Myers Squibb buys Nvidia AI system for drug discovery - AI News
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):